The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwHRMM 2025 | The clinical significance of translocation 4;14 in multiple myeloma
Mattia D’Agostino, MD, University of Turin, Turin, Italy, discusses the implications of the translocation 4;14 in multiple myeloma. He notes that it is associated with a unique biology driven by the hyperexpression of MMSET, making it a high-risk feature with important prognostic and potential therapeutic implications. This interview took place at the 2nd International Workshop on High-Risk Multiple Myeloma (iwHRMM 2025), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Translocation 4;14 is found in approximately 10 to 15 percent of newly diagnosed multiple myeloma patients and through hyperexpression of MMSET. It really drives a unique biology that we can observe also clinically because this alteration is considered one of the high-risk features. So with the genomics we can really dig down into these disease subsets. So this is important prognostically and hopefully in the future also therapeutically...
Translocation 4;14 is found in approximately 10 to 15 percent of newly diagnosed multiple myeloma patients and through hyperexpression of MMSET. It really drives a unique biology that we can observe also clinically because this alteration is considered one of the high-risk features. So with the genomics we can really dig down into these disease subsets. So this is important prognostically and hopefully in the future also therapeutically.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
